SCHEMBL4081854

SCHEMBL4081854

CC(C)[Si](F)(c1ccc(COC2CCCCO2)cc1)C(C)C

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 1/20 0.40
SELE P16581 1/20 0.40
KDM4C Q9H3R0 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CREBBP Q92793 2/20 0.35
TACR1 P25103 2/20 0.34
EP300 Q09472 1/20 0.34
P2RX3 P56373 5/20 0.34
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13933489 0.87 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4078449 0.87 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL4081717 0.86 ICAM1 (0.38) ICAM1SELEKDM4CL3MBTL1NPC1
SCHEMBL4072226 0.85 MEN1 (0.42) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL14228857 0.83 ICAM1 (0.39) ICAM1SELEKDM4CL3MBTL1NPC1
SCHEMBL31120322 0.79 TACR1 (0.45) ICAM1SELEKDM4CMEN1KMT2A
SCHEMBL12141797 0.79 ICAM1 (0.42) ICAM1SELEKDM4CL3MBTL1NPC1
SCHEMBL3999018 0.79 ICAM1 (0.42) ICAM1SELEKDM4CL3MBTL1NPC1
SCHEMBL14065905 0.79 ICAM1 (0.42) ICAM1SELEKDM4CL3MBTL1NPC1
SCHEMBL22859636 0.78 ICAM1 (0.39) ICAM1SELEKDM4CL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 EP disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035215-A1 RADIOFLUORINATION AFF2, AFF1, NUTF2 ICAM1 2963/4885SELE 3071/4885KDM4C 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.